Efficacy of shatapushpa taila matra basti with oral administraion of yograja guggulu and kumaryasava in polycystic ovarian syndrome

Efficacy of shatapushpa taila matra basti with oral administration of yograja guggulu and kumaryasava in the management of polycystic ovarian syndrome A single arm clinical study - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/098988

Enrollment

Registered

2025-12-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 Female patient aged 18 to 40 years married or unmarried diagnosed with PCOS by Rotterdam Criteria must meet at least 2 of 3 Anovulation oligo or amenorrhea Hyperandrogenism clinical or biochemical Polycystic ovaries on ultrasound A polycystic ovary is defined as an ovary containing 12 or more follicles or 25 or more follicles using new ultrasound technology measuring 2 to 9 mm in diameter or an ovary that has a volume of greater than 10 mL on ultrasonography 2 Patient must be willing to provide voluntary informed consent 3 NIH Criteria 1990 To include both of the following Oligo ovulation Hyperandrogenism 4 AE PCOS 2009 1 Hyperandrogenism hirsutism and or hyperandrogenemia 2 Ovarian dysfunction Oligo-anovulation and or polycystic ovaries 3 Exclusion of other androgen excess or related disorders

Exclusion criteria

Exclusion criteria: a Primary amenorrhea b Pregnancy c Pelvic systemic conditions causing oligo anovulation or other gynecological disorders endometriosis hydrosalpinx uterine fibroids d Endocrine disorders unrelated to PCOS thyroid disease hyperprolactinemia congenital adrenal hyperplasia pituitary adenomas e Organic reproductive tract lesions tuberculosis malignancy carcinoma f Chronic systemic disease hypertension diabetes liver or renal disease Cushing s syndrome cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Reduction in ovarian volume in USG pelvis findingsTimepoint: Reduction in ovarian volume in USG pelvis findings in 3 months	—

Secondary

Measure	Time frame
Regulation of menstrual cycle hormonal profile decreases acne BMI hirsutismTimepoint: Regulation of menstrual cycle in 3months	—

Countries

India

Contacts

Public ContactDr Sujata kadam

All india institute of ayurveda

sujatadkadam@gmail.com9890305370

Outcome results